Evidence map›Paper›PMID 20008281›Full record

ArticleAmerican journal of respiratory cell and molecular biology2010

Dynamics of human complement-mediated killing of Klebsiella pneumoniae.

Christina M Nypaver, Margaret M Thornton, Suellen M Yin, David O Bracho, Patrick W Nelson, Alan E Jones, David M Bortz, John G Younger

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Increased Alternative Complement Pathway Function and Improved Survival during Critical Illness.American journal of respiratory and critical care medicine · 2020
    Article
  3. A review of quantitative modeling of B cell responses to antigenic challenge.Journal of pharmacokinetics and pharmacodynamics · 2014
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Christina M NypaverDepartment of Emergency Medicine, University of Michigan, Ann Arbor, Michigan 48109-3300, USA.
Margaret M Thornton
Suellen M Yin
David O Bracho
Patrick W Nelson
Alan E Jones
David M Bortz
John G Younger
University of Michigan · USCarolinas Medical Center · USUniversity of Colorado Boulder · US

Funding

Complement C5A in Human SepsisR01GM069438 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YOUNGER, JOHN G · 2004 to 2014
$3.2M
Randomized Clinical Trial of a Less-Invasive Resuscitation Protocol for SepsisK23GM076652 · NIGMS · CAROLINAS MEDICAL CENTER · PI JONES, ALAN E · 2006 to 2010
$699k
NIGMS NIH HHS GM069438NIGMS NIH HHS GM076652Wellcome Trust
6 · The paper itself

Abstract

With an in vitro system that used a luminescent strain of Klebsiella pneumoniae to assess bacterial metabolic activity in near-real-time, we investigated the dynamics of complement-mediated attack in healthy individuals and in patients presenting to the emergency department with community-acquired severe sepsis. A novel mathematical/statistical model was developed to simplify light output trajectories over time into two fitted parameters, the rate of complement activation and the delay from activation to the onset of killing. Using Factor B-depleted serum, the alternative pathway was found to be the primary bactericidal effector: In the absence of B, C3 opsonization as measured by flow cytometry did not progress and bacteria proliferated near exponentially. Defects in bacterial killing were easily demonstrable in patients with severe sepsis compared with healthy volunteers. In most patients with sepsis, the rate of activation was higher than in normal subjects but was associated with a prolonged delay between activation and bacterial killing (P < 0.05 for both). Theoretical modeling suggested that this combination of accentuated but delayed function should allow successful bacterial killing but with significantly greater complement activation. The use of luminescent bacteria allowed for the development of a novel and powerful tool for assessing complement immunology for the purposes of mechanistic study and patient evaluation.

Indexed as

Anti-Bacterial AgentsComplement C3Complement System ProteinsHealthHumansKlebsiella pneumoniaeLuminescent MeasurementsMicrobial ViabilityOpsonin ProteinsSepsisSerumTime FactorsAnti-Bacterial AgentsComplement C3Complement System ProteinsOpsonin Proteins

Identifiers

PMID20008281
PMCPMC2970855
OpenAlexW1987442161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.